SMO and meningioma: Additionally, alterations in other genes such as SMO, AKT1, TRAF7, and KLF4 have been identified, particularly in non-NF2 mutant meningiomas, indicating a heterogeneous molecular landscape that may influence both prognosis and treatment response [42].